31 completed, 9 terminated, 3 unknown, 1 active not recruiting. 11 Phase 2, 10 Phase 3, 5 Phase 4, 1 Not applicable, 1 Phase 1.
Follow GWT-TUD GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. Luspatercept - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | GWT-TUD GmbH | 70 | 2021-10-27 | 2025-09-30 |
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | GWT-TUD GmbH | 306 | 2021-04-30 | 2026-06-10 |
| Emicizumab in Acquired Hemophilia A Emicizumab Injection - Hemophilia A, Acquired | Phase 2 | Completed | GWT-TUD GmbH | 47 | 2021-03-23 | 2023-01-09 |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer Romidepsin, Azacitidine, nab-Paclitaxel - Pancreas Cancer, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | GWT-TUD GmbH | 75 | 2020-05-25 | 2025-09-30 |
| Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Nivolumab, relatlimab, Oxaliplatin - Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | Phase 2 | Unknown | University Hospital, Essen | 21 | 2019-09-26 | 2024-03-12 |
| Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML CPX-351, Daunorubicin, Cytarabine - MDS, AML | Phase 2 | Completed | GWT-TUD GmbH | 150 | 2019-08-19 | 2026-09-10 |
| ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy High dose chemotherapy before allogeneic stem cell transplantation (alloSCT), Bone marrow histology, clinical and laboratory parameters - Aggressive Non-hodgkin Lymphoma (aNHL), Lymphoma, B-Cell | Phase 2 | Completed | GWT-TUD GmbH | 60 | 2019-06-24 | 2023-05-24 |
| Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Bemcentinib - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 2 | Completed | GWT-TUD GmbH | 45 | 2018-12-20 | 2021-12-21 |
| Study in Patients With Chronic Leukemia Ponatinib - Leukemia, Myeloid, Chronic-Phase | Phase 2 | Terminated | GWT-TUD GmbH | 18 | 2018-12-11 | 2023-09-14 |
| Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib pazopanib or guideline conform chemotherapy - Soft Tissue Sarcoma Adult | Phase 4 | Terminated | GWT-TUD GmbH | 11 | 2018-11-02 | 2021-09-22 |
| Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma MLN9708, Pomalidomide 4 MG Oral Capsule, Dexamethasone - Refractory Multiple Myeloma | Phase 2 | Completed | GWT-TUD GmbH | 66 | 2018-09-20 | 2025-09-30 |
| Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Secukinumab 300 mg, Placebo - Dermatitis, Atopic, Eczema, Atopic | Phase 2 | Completed | GWT-TUD GmbH | 22 | 2018-09-18 | 2021-05-03 |
| EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations Iron Supplement - Iron-deficiency | Completed | GWT-TUD GmbH | 51 | 2018-01-16 | 2019-07-02 | |
| Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry PCSK9 Inhibitor [EPC], Standard lipid lowering therapy - Dyslipoproteinemias, Hypercholesterolemia, Familial | Completed | GWT-TUD GmbH | 1695 | 2017-05-18 | 2025-05-09 | |
| Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS) No Intervention - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Completed | GWT-TUD GmbH | 72 | 2017-02-02 | 2022-04-04 | |
| Study of Vascular Function Before vs After Smoking an E-cigarette as Compared to a Normal Cigarette electronic cigarette (e-cigarette), conventional tobacco cigarette - Endothelial Function | Terminated | GWT-TUD GmbH | 64 | 2017-01-09 | 2022-10-28 | |
| Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) HyQvia - Primary Immunodeficiency, Secondary Immune Deficiency | Completed | GWT-TUD GmbH | 156 | 2016-12-22 | 2023-09-14 | |
| Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY JNJ-56022473, Bone marrow analyses and CBC with differential, Flow cytometry analyses - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | GWT-TUD GmbH | 25 | 2016-07-01 | 2018-10-25 |
| Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease Parkinson's Disease | Completed | GWT-TUD GmbH | 50 | 2016-06-01 | 2022-07-22 | |
| INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis any drug, any procedure/surgery, Any non-pharmacological treatment of SVT - Superficial Vein Thrombosis | Completed | GWT-TUD GmbH | 1210 | 2016-04-14 | 2023-09-14 |
Showing 20 of 45. Sign in to see all of them.
Diabetes Mellitus, Type 2 (8) · Chronic Limb-Threatening Ischemia (2) · Diabetes Mellitus (2) · Diabetic Foot (2) · Dyslipidemias (2) · Leukemia, Myeloid, Acute (2) · Metabolic Syndrome (2) · Myelodysplastic Syndromes (2) · Primary Immunodeficiency Diseases (2) · Sarcoma (2) · Acne Vulgaris (1) · Anemia, Iron-Deficiency (1) · Bronchiolitis Obliterans Syndrome (1) · Dermatitis, Atopic (1) · Disease (1)
Acarbose (2) · Azacitidine (2) · Rivaroxaban (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Aspirin (1) · Blood Cell Count (1) · CPX-351 (1) · Carboplatin (1) · Clindamycin (1) · Colesevelam Hydrochloride (1) · Cyclophosphamide (1) · Cytarabine (1) · Cytogenetic Analysis (1) · Daunorubicin (1)
Germany (44) · Austria (6) · France (4) · Switzerland (4) · Belgium (2) · Italy (2) · Spain (2) · Hungary (1) · Netherlands (1) · United Kingdom (1) · United States (1)
David Pittrow, MD, PhD (6) · Uwe Platzbecker, Prof. (3) · David Pittrow, MD (2) · Jan Beyer-Westendorf, MD (2) · Markolf Hanefeld, Prof. Dr. (2) · Michael Borte, MD, PhD (2) · S. Schellong, Prof.Dr.med. (2) · Wilhelm Kirch, MD, PhD (2) · Andreas Birkenfeld, MD, PhD (1) · Andreas Tiede, Prof. Dr. (1) · Antje Bergmann, Prof.Dr.med. (1) · Ardeschir H. Ghofrani, MD, PhD (1) · Axel R. Heller, MD (1) · Ben MW Illigens, MD (1) · Bernd Hohenstein, MD, PhD (1)
PMID 19156626, PMID 22434180, PMID 22976553, PMID 23164592, PMID 23430192, PMID 23720182, PMID 24081973, PMID 24859362, PMID 25739533, PMID 25837040, PMID 26630396, PMID 26973347, PMID 27134672, PMID 28219692, PMID 28467615, PMID 28603514, PMID 28667207, PMID 28709421, PMID 28775047, PMID 28991900, PMID 29134606, PMID 29368137, PMID 29450722, PMID 29599117, PMID 29628397, PMID 30337446, PMID 30876420, PMID 32335423, PMID 32381492, PMID 32414075, PMID 32727496, PMID 32859662, PMID 33313046, PMID 33368114, PMID 33581097, PMID 34210599, PMID 34495376, PMID 34737226, PMID 35070795, PMID 35777416, PMID 36178485, PMID 36333206, PMID 36370650, PMID 36773001, PMID 37036560, PMID 37105586, PMID 37462520, PMID 37573936, PMID 37802633, PMID 37858328
2016 (1)